Original Research

Antiepileptic and Neuroprotective Effects of Rheum tanguticum Root Extract on Trimethyltin-Induced Epilepsy and Neurodegeneration: In Vivo and in Silico Analyses

Jae-young Choi1,‡, Sohi Kang1,‡, Minh Nhat Tran3,4,5, Sanghun Lee3,4, Seung Mok Ryu6, Sung-Wook Chae6,7, Do-Hyun Kim8, Ye Eun Lee8, Sohee Jeong2, Changjong Moon2, Joong Sun Kim2,*, Soong-In Lee8,*

1Namdaernam Sehwa Korean Medical Clinic, 04529 Seoul, Republic of Korea
2Departments of Veterinary Anatomy and Animal Behavior, College of Veterinary Medicine and BK21 FOUR Program, Chonnam National University, 6186 Gwangju, Republic of Korea
3Korean Medicine Data Division, Korea Institute of Oriental Medicine, 34054 Daejeon, Republic of Korea
4Korean Convergence Medical Science, University of Science and Technology, 34113 Daejeon, Republic of Korea
5Faculty of Traditional Medicine, Hue University of Medicine and Pharmacy, Hue University, 49000 Thua Thien Hue, Vietnam
6Herbal Medicine Resources Research Center, Korea Institute of Oriental Medicine, 58245 Naju-si, Jeollanam-do, Republic of Korea
7Center for Companion Animal New Drug Development, Jeonbuk Branch, Korea Institute of Toxicology, 56212 Jeongeup, Jeollabuk-do, Republic of Korea
8Department of Oriental Medicine, College of Oriental Medicine, Dongshin University, 58245 Naju-si, Jeollanam-do, Republic of Korea

*Correspondence: centralline@jnu.ac.kr (Joong Sun Kim); barunhani@dsu.ac.kr (Soong-In Lee)

These authors contributed equally.

Academic Editors: Jesús Pastor and Gernot Riedel

Submitted: 28 November 2023 Revised: 5 February 2024 Accepted: 5 March 2024 Published: 21 June 2024

Abstract

Background: Rheum tanguticum root, cataloged as “Daehwang” in the Korean Pharmacopeia, is rich in various anthraquinones known for their anti-inflammatory and antioxidant properties. Formulations containing Daehwang are traditionally employed for treating neurological conditions. This study aimed to substantiate the antiepileptic and neuroprotective efficacy of R. tanguticum root extract (RTE) against trimethyltin (TMT)-induced epileptic seizures and hippocampal neurodegeneration. Methods: The constituents of RTE were identified by ultra-performance liquid chromatography (UPLC). Experimental animals were grouped into the following five categories: control, TMT, and three TMT+RTE groups with dosages of 10, 30, and 100 mg/kg. Seizure severity was assessed daily for comparison between the groups. Brain tissue samples were examined to determine the extent of neurodegeneration and neuroinflammation using histological and molecular biology techniques. Network pharmacology analysis involved extracting herbal targets for Daehwang and disease targets for epilepsy from multiple databases. A protein-protein interaction network was built using the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database, and pivotal targets were determined by topological analysis. Enrichment analysis was performed using the Database for Annotation, Visualization, and Integrated Discovery (DAVID) tool to elucidate the underlying mechanisms. Results: The RTE formulation was found to contain sennoside A, sennoside B, chrysophanol, emodin, physcion, (+)-catechin, and quercetin-3-O-glucuronid. RTE effectively inhibited TMT-induced seizures at 10, 30, and 100 mg/kg dosages and attenuated hippocampal neuronal decay and neuroinflammation at 30 and 100 mg/kg dosages. Furthermore, RTE significantly reduced mRNA levels of tumor necrosis factor (TNF-α), glial fibrillary acidic protein (GFAP), and c-fos in hippocampal tissues. Network analysis revealed TNF, Interleukin-1 beta (IL-1β), Interleukin-6 (IL-6), Protein c-fos (FOS), RAC-alpha serine/threonine-protein kinase (AKT1), and Mammalian target of rapamycin (mTOR) as the core targets. Enrichment analysis demonstrated significant involvement of R. tanguticum components in neurodegeneration (p = 4.35 × 10^-2) and TNF signaling pathway (p = 9.94 × 10^-5). Conclusions: The in vivo and in silico analyses performed in this study suggests that RTE can potentially modulate TMT-induced epileptic seizures and neurodegeneration. Therefore, R. tanguticum root is a promising herbal treatment option for antiepileptic and neuroprotective applications.

Keywords: neurodegenerative disorders; inflammation; epilepsy; Rheum tanguticum; network pharmacology

1. Introduction

Rheum tanguticum Maxim. ex Balf. is a perennial plant belonging to the genus Rheum L. of the Polygonaceae family [1]. Its roots, known as Daehwang (or Da Huang in Chinese), have a long history of medicinal use in China, Korea, and Japan [2]. In Korea, Daehwang is clinically administered for a range of conditions, including constipation, abdominal pain, diarrhea, jaundice, nosebleeds, conjunctivitis, sore throat, appendicitis, bruises, amenorrhea, and burns [3]. Formulations such as Daeunggutang (Da Cheng Qi Tang), Dohoakseunggutang (Taohe Chengqi Tang), Jeodangtang (Di Dang Tang), and Sasihtag (San Huang Xie Xin Tang) all incorporate Daehwang. Various neurological symptoms, including perceptions of see-
Epilepsy is a neurological disorder characterized by recurrent seizures arising from various etiological factors and complex initiation mechanisms [12]. Factors such as congenital brain anomalies, abnormal neuronal migration, birth trauma, intracerebral hemorrhage, intracranial inflammation, febrile seizures, hypoxia, hypoglycemia, hydrocephalus, brain injury, intracranial tumors, and cerebrovascular diseases are attributed to the onset of epilepsy [13]. In Korea, the incidence of epilepsy ranges from 50 to 70 cases per 100,000 individuals annually, ranking it as the third most prevalent neurological condition after dementia and stroke. Within 5 years after an initial seizure, approximately 80% of patients are likely to experience a subsequent seizure, evolving into chronic active epilepsy. Roughly 30% of patients with epilepsy exhibit drug resistance [14,15]. Consequently, the mean disease duration spans 10 years, with 20–30% of cases manifesting as lifelong conditions. Considering these circumstances, there is a pressing need for innovative therapeutic approaches for seizure management. Following the emergence of the epilepsy-epileptogenesis paradigm, the focus has shifted toward understanding the mechanistic links between inflammation and epilepsy [16–18]. In this context, our research aims to investigate the efficacy of natural products in trimethyltin (TMT)-induced epilepsy models.

The organotin compound, TMT exhibits specific toxicity in the hippocampus, an essential part of the brain’s limbic system [19]. TMT exposure is associated with a range of neurological symptoms, such as hypoactivity evolving into hyperactivity, hyperekctability, ataxia, tremors, seizures, convulsions, memory deficits, and learning impairments, collectively termed TMT syndrome [20,21]. Consequently, TMT is used to simulate neurodegenerative conditions, such as epilepsy and dementia in animal models [22,23], and the hippocampal damage closely resembles that caused by convulsant agents or observed in certain human epilepsy cases [24]. The neurotoxic effects of TMT are attributed to multiple mechanisms, including apoptotic cell death, calcium dyshomeostasis, oxidative stress, and neuroinflammation [25]. Much like kainic acid, commonly used to study temporal lobe epilepsy and status epilepticus, TMT induces neuronal loss in the CA3 and CA1 regions of the hippocampus [26]. This loss is thought to result from either glutamate-dependent excitotoxicity or calcium overload [23]. When glutamate receptor antagonists are co-administered with TMT, excitotoxicity is reduced, suggesting potential neuroprotective benefits [27]. Therefore, TMT is a valuable tool for generating animal models of neurodegeneration associated with cognitive decline and temporal lobe epilepsy. This is because the neurodegenerative effects of TMT share key pathogenic features common to a broad array of neurodegenerative disorders, such as selective neuronal death and neuroinflammation [23,28].

The onset of symptoms in neurodegenerative diseases is frequently linked to neuroinflammation. Proinflammatory elements, including activated glial cells and microglia, have garnered significant interest as potential therapeutic targets for individuals with epilepsy [29]. An analysis of the dementia drug development pipeline in 2023 delineated the roles of candidate therapies aimed at amyloid, epigenetics, inflammation/immunity, metabolism/bioenergetics, neurogenesis, neurotransmitter receptors, and oxidative stress [30]. Therefore, this study sought to assess the regulatory efficacy of R. tanguticum in animal models of seizures and hippocampal neurodegeneration induced by TMT.

Identification of complex molecular pathways remains a substantial challenge in the context of herbal medications. Unlike single-compound agents, herbal medications usually comprise multiple components, complicating the task of elucidating specific action mechanisms [31]. Network pharmacology has recently emerged as a new approach for identifying compound-target pathways related to particular diseases, offering a systematic and holistic perspective. Despite advances in clarifying the actions of various herbs and pharmacological agents through network pharmacology’s “multi-target–multi-pathway” frameworks, the molecular mechanisms accounting for the effectiveness of R. tanguticum in epilepsy treatment remain undefined.

In this study, the therapeutic potential of R. tanguticum for epilepsy was evaluated by integrating experimental research with network pharmacology. Initially, a mouse model was employed to investigate the protective effects against TMT-induced hippocampal degeneration. Subsequently, a network pharmacological analysis was conducted to comprehensively evaluate the regulatory mechanisms involved in epilepsy treatment, focusing on potential active compounds and target genes (Fig. 1).
2. Materials and Methods

2.1 Herbal Medicine Extraction

Decoction has been one of the most widely used methods for extracting herbal ingredients in traditional Chinese medicine. We extracted *R. tanguticum* using the decoction method as used in *Gejigadaehwang-tang*, whose neuroprotective effects were previously confirmed [32]. *R. tanguticum* was commercially acquired from Nanumherb Co., Ltd. (Gyeongbuk, Korea; product number: HA1900240302; origin: Shaanxi, China; plant parts used: root and rhizome). The *R. tanguticum* root extract (RTE) was prepared by performing cooling reflux extraction for 2.5 h using 1.0 L distilled water as the solvent at 100 ± 2 °C after maceration for 1 h at 4 °C. The extract was subsequently passed through filter paper (6 µm, No. 1, Advantec MFS Inc., Tokyo, Japan), concentrated using a vacuum evaporator (N-1000; EYELA, Bohemia, NY, USA) at 70 °C, and lyophilized using a freeze dryer (FD8512; Ilsin Lab Co., Ltd., Daejeon, Republic of Korea). The extraction efficiency during a single production of RTE was 13.7% (13.7 g powder was extracted from 100 g dried *R. tanguticum*). The extracted powder was stored in a freezer at −20 °C. Before oral administration, lyophilized RTE was reconstituted in water.

2.2 Composition Analysis

For the ultra-performance liquid chromatography (UPLC; Acquity UPLC, Waters, MA, USA) analysis, RTE (2 mg/mL) and standard compounds (0.2 mg/mL) were solubilized in water. The standard compounds used were sennoside B, sennoside A, chrysophanol, physcion (Ministry of Food and Drug Safety, Cheongju, Republic of Korea), emodin, (+)-catechin (Sigma-Aldrich, St. Louis, MO, USA), and quercetin-3-O-glucuronoid (ChemFace, Wuhan, Hubei, China). The mobile phase consisted of 0.1% formic acid in water (A) and 0.1% formic acid in acetonitrile (B). Chromatography began with an initial 5% proportion of solvent B, which was then linearly increased to 50% over a span of 20 min. The samples were loaded on an Acquity UPLC C18 column (1.7 × 2.1 × 100 mm, Waters, MA, USA).
2.3 Animal Experiments

Eight-week-old male C57BL/6 mice were sourced from Central Lab Animal Inc. (Seoul, Republic of Korea) and given a week to acclimatize. Female mice demonstrate variable social behavior dependent on their estrus cycle [33]; hence, their use in neuroscience research necessitates documenting estrus stages and modifying test protocols accordingly [34]. To preclude such variables from influencing the data, only male mice were utilized in this study. The animals were housed under the following controlled environmental conditions: 23 ± 2 °C temperature, 50 ± 5% relative humidity, and a 12-h artificial light cycle (08:00–20:00). A standard diet was provided to the mice.

All experimental procedures were conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee at Dongshin University (approval no.: DSU2023-04-03). The mice were divided into the following five groups: group 1, control; group 2, TMT; group 3, TMT+RTE (10 mg/kg); group 4, TMT+RTE (30 mg/kg); and group 5, TMT+RTE (100 mg/kg). The RTE dosages were determined based on both the no-observed-adverse-effect-level (NOAEL) of rhubarb mg/kg). The RTE dosages were determined based on both the no-observed-adverse-effect-level (NOAEL) of rhubarb for chronic toxicity [35] and the 10% Daehwang content in Geijigadaehwang-tang [32], as previously determined in our study regarding neuroprotective efficacy. On day 0, TMT (Wako, Osaka, Japan) was administered intraperitoneally at a dosage of 2.6 mg/kg after diluting in saline. RTE was initially administered orally 1 h before TMT injection and subsequently twice daily, considering pharmacokinetics of the rhubarb anthraquinones [36]. Monitoring activities, including RTE administration, seizure assessment, and weight measurement, were performed daily between 09:30 and 10:30. RTE doses were administered at 09:30 and 15:30. On day 2, when neurotoxicity and clinical symptoms were most manifested, the mice were euthanized [25,37] by intravenously injecting a combination of alfaxalone (Rompun®), 85 mg/kg; Jurox Pty Ltd., Rutherford, NSW, Australia) and xylazine (10 mg/kg, Bayer Korea, Seoul, Republic of Korea).

2.4 Measurement of Seizures

Seizure behavior was assessed using a bright box (dimensions: 40 × 40 cm; illumination: 250 lx), following the protocol outlined in a previous study [38]. Behavioral changes were categorized into the following five stages: 1 = aggressive behavior, 2 = weak tremor, 3 = systemic tremor, 4 = tremor with spasmodic gait, and 5 = death. Seizure evaluation was visually assessed 3 days before, 1 day before, on the day of, 1 day after, and 2 days after TMT treatment.

2.5 Quantitative Reverse Transcription-Polymerase Chain Reaction (qRT-PCR) Analysis

The procedure for quantitative reverse transcription-polymerase chain reaction (qRT-PCR) analysis is extensively documented in the literature [39]. Hippocampal tissue was processed to extract total RNA using the Hybrid R Kit (GeneAll Biotechnology, Seoul, Republic of Korea). The NanoDrop ND-2000 system (Thermo Fisher Scientific, Waltham, MA, USA) was used to assess the concentration of RNA. Reverse transcription of 1 μg RNA was performed using the PrimeScript RT master mix according to the manufacturer’s guidelines (Takara, Tokyo, Japan). qRT-PCR was conducted in triplicate using the CFX360 Real-Time system (Bio-Rad, Hercules, CA, USA) and SYBR Green qPCR master mix (MBIotech, Hanam, Korea). The ΔΔCT method was used to normalize the expression levels of target genes against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as the reference. The primers for mouse genes were as follows: tumor necrosis factor α (TNF-α) 5′-CCCTCACACTCATCATTCTTCT-3′ and 5′-GCTACGACGTGGGCTACAG-3′, glial fibrillary acidic protein (GFAP) 5′-AGAAAAACCGCATCACC TTC-3′ and 5′-TCTCACCAGTCTTACACCG-3′, c-fos 5′-GGGCTGCACTATTACAGT-3′ and 5′-TG CCTGCTCTTCTGACTG-3′, GAPDH 5′-CAGCATACTACGACCCAGG-3′ and 5′-CCATACAGCCCCCTCATT-3′. The crossing threshold values for the individual genes were normalized to GAPDH expression.

2.6 Immunohistochemistry

The immunohistochemistry technique has been previously described in detail [39]. Sections of deparaffinized tissue were treated with primary antibodies, namely rabbit anti-doublecortin (DCX; Cell Signaling Technology, Beverly, MA, USA), GFAP (Cell Signaling Technology), and ionized calcium-binding adaptor molecule 1 (Iba-1; Wako Pure Chemical Industries, Ltd., Osaka, Japan). After washing with phosphate-buffered saline (PBS), the sections were incubated using biotinylated anti-rabbit IgG (Vector Laboratories, New York, CA, USA). The Vector ABC Elite kit (Vector Laboratories) was used for detection of specific binding with a 3,3-diaminobenzidine tetrahydrochloride solution. The Motic Easyscan Digital Slide Scanner (Motic, Hong Kong, China) was used to analyze the stained sections. The ImageJ software was used for quantification of staining intensity in the hippocampus (NIH, Bethesda, MD, USA).

2.7 In Silico Identification of Active Compounds in R. tanguticum for Treating Epilepsy

Compounds associated with R. tanguticum were combined from UPLC analysis and databases, including Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP, https://tcmsps e.com/tcmsp.php), version 2.3 [40] and Herbal-Ingredient-Target Platform (HIT, http://hit2.badd-cao.net/), version 2.0 [41] using “Da huang” or “Dahuang” as search terms. The retrieved compounds’ synonym names, Chemical Abstracts Service (CAS) numbers, PubMed com-
2.8 In Silico Identification of Target Genes of R. tanguticum for Treating Epilepsy

The active compounds of R. tanguticum and their corresponding target genes were retrieved from multiple databases, namely TCMSP version 2.3 [40], HIT version 2.0 [41], Bioinformatics Analysis Tool for Molecular mechANism of TCM (BATMAN-TCM, http://biobet.ncpsb.org/batman-tcm) [44], and SWISS-TargetPrediction (http://www.swisstargetprediction.ch/) [45]. Compound names, CIDs, and CAS numbers were entered in the HIT 2.0 system of the TCMSP (https://tcmsp-e.com/tcmsp.php) and HIT (http://hit2.badd-cao.net/) databases to extract target gene information. For BATMAN-TCM, the CIDs of compounds were submitted by selecting predicted potential genes, including known associates, with a score cutoff set at 20. The SWISS Target Prediction required a probability filter threshold of 0.1 to determine relevant genes. The collected target genes were then cross-referenced for accuracy regarding gene IDs and nomenclature using the UniProt database (https://www.uniprot.org/), focusing on the species “Homo sapiens”.

Subsequent steps involved identifying epilepsy-associated disease targets using DisGeNET version 7.0 (https://www.disgenet.org/) [46], Genecards version 5.9 (https://www.genecards.org/) [47], and the Therapeutic Target Database (TTD, https://db.idrblab.net/xtt/) [48]. Criteria for selection included all disease targets from TTD and those with a gene-disease association score exceeding 0.1 in DisGeNET as well as targets with a relevance score surpassing 10 in Genecards. Common targets between R. tanguticum compounds and epilepsy were earmarked for further analysis.

2.9 In Silico Construction of Protein-Protein Interaction (PPI) Network and Analysis of Signaling Pathways

To examine the protein interactions among the overlapping targets, a protein-protein interaction (PPI) network was constructed. This was facilitated by the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING, https://string-db.org/) database, with the species set to “H. sapiens” and a medium confidence score threshold of 0.4 [49]. The network topology was subsequently analyzed using Cytoscape 3.9.0 (U.S. National Institute of General Medical Sciences, Bethesda, MD, USA), where centrality of the nodes was quantified by the degrees, indicative of the number of linkages per node [50].

To elucidate the biological processes and molecular pathways implicated in the treatment of epilepsy by R. tanguticum, enrichment analysis involving Gene Ontology (GO, https://geneontology.org/) and Kyoto Encyclopedia of Genes and Genomes (KEGG, https://www.genome.jp/kegg/) pathways was conducted using the Database for Annotation, Visualization, and Integrated Discovery (DAVID, https://david.ncifcrf.gov/). In this analysis, an adjusted cut-off p-value of 0.01 was applied after Benjamini’s correction [51]. The GO analysis addressed the molecular functions, cellular components, and biological processes associated with the targets, while the KEGG pathway analysis explored the targets’ roles in diverse pathways and processes. A comprehensive “herb-compound-target-pathway” network was also constructed using Cytoscape 3.9.0 to delineate the action mechanisms of RT [50].

2.10 Statistical Analysis

The results are presented as the mean ± standard error of the mean (SEM). For multiple comparisons, one-way analysis of variance followed by the Student–Newman–Keuls post hoc test was employed. Analytical graphs were generated using GraphPad Prism 8 (GraphPad Software, San Diego, CA, USA). A p-value < 0.05 was considered statistically significant.

3. Results

3.1 Main Components of RTE

The chemical constituents of RTE were characterized using UPLC under optimized chromatographic conditions. The analysis revealed the presence of (+) catechin, sennoside B, quercetin-3-o-glucuronoid, sennoside A, physcion, emodin, and chrysophanol, which were consistent with standard references when subjected to identical analytical conditions (Fig. 2). In addition, the quantitative analysis results were summarized in Table 1.

3.2 Inhibitory Efficacy of RTE against TMT-Induced Seizures and Neurodegeneration

Fig. 3A illustrates the experimental schedule, as detailed in section 2. We evaluated the protective effects of RTE against seizures induced by TMT toxicity using groups of 8–9 mice. RTE was administered orally to the mice 1 h before TMT administration and subsequently, twice daily. After TMT administration, the mice demonstrated aggressive behavior, reduced body weight, convulsions, and seizure activity from the first day. A marked reduction in body weight was observed in the TMT group on the first
2 days (day 0: 21.4 ± 0.2 g, day 1: 19.5 ± 0.4 g, and day 2: 18 ± 0.8 g). In contrast, RTE ameliorated weight reduction in a dose-dependent manner (day 2: 19.9 ± 0.3 g, 20.3 ± 0.2 g, and 20.1 ± 0.4 g for the TMT+RTE10, TMT+RTE30, and TMT+RTE100 groups, respectively; Fig. 3B).

The severity of seizures was found to have intensified on the second day relative to that of those on the first day, which conforms to the results of previous studies [25,37]. Initially, the TMT group exhibited a seizure severity score of 3.5 ± 0.2, exceeding that of the RTE groups (2.9 ± 0.1, 2.7 ± 0.2, and 2.8 ± 0.2 for TMT+RTE10, TMT+RTE30, and TMT+RTE100 groups, respectively). On the following day, seizure severity in the TMT group rose to 3.8 ± 0.2, which was notably higher than the scores in all the RTE groups. The reduction in seizure severity of the RTE groups appeared to be dose-responsive (3.4 ± 0.1, 3.2 ± 0.2, and 2.9 ± 0.2 for TMT+RTE10, TMT+RTE30, and TMT+RTE100 groups, respectively). Therefore, RTE administration is associated with reduced seizure severity (Fig. 3C).

A significant relationship exists between the severity of seizures and neuronal death [52]. DCX-positive immature progenitor neurons in the dentate gyrus (DG) substantially decreased 2 days after TMT administration—from 1.00 ± 0.17 in the control (CON) group to 0.25 ± 0.02 in the TMT group. In contrast, treatment with RTE mitigated

---

**Table 1. Calibration curves and content of standard compounds in RTE.**

<table>
<thead>
<tr>
<th>Compound</th>
<th>Calibration equation</th>
<th>$r^2$</th>
<th>Content (mg/g, %)</th>
</tr>
</thead>
<tbody>
<tr>
<td>(+) catechin</td>
<td>$y = 19366x - 1839.1$</td>
<td>1.00</td>
<td>$25.51 ± 0.03 (2.551)$</td>
</tr>
<tr>
<td>sennoside B</td>
<td>$y = 20111x - 5010.0$</td>
<td>1.00</td>
<td>$7.17 ± 0.01 (0.717)$</td>
</tr>
<tr>
<td>quercetin-3–O-glucuronoid</td>
<td>$y = 20027x - 9564.7$</td>
<td>0.99</td>
<td>$10.76 ± 0.01 (1.764)$</td>
</tr>
<tr>
<td>sennoside A</td>
<td>$y = 24097x - 3675.5$</td>
<td>0.99</td>
<td>$5.07 ± 0.01 (0.507)$</td>
</tr>
<tr>
<td>physcion</td>
<td>$y = 57438x - 1720.2$</td>
<td>0.99</td>
<td>$1.32 ± 0.01 (0.132)$</td>
</tr>
<tr>
<td>emodin</td>
<td>-</td>
<td>-</td>
<td>trace</td>
</tr>
<tr>
<td>chrysophanol</td>
<td>-</td>
<td>-</td>
<td>trace</td>
</tr>
</tbody>
</table>

* Content results are shown as mean ± standard deviation (SD) (n = 3 per group).
neuronal loss in two groups (0.61 ± 0.12 for TMT+RTE30 and 0.50 ± 0.06 for TMT+RTE100, Fig. 3D,E).

3.3 Protective Effects of RTE as Demonstrated by Synaptic and Neuroinflammatory mRNA Expression Levels in the Hippocampus of TMT-Treated Mice

Fig. 4 illustrates the marked elevation in mRNA expressions of *c-fos* (9.8 ± 1.9), *TNF-α* (42.3 ± 19.8), and *GFAP* (4.9 ± 1.5) in the hippocampus of the TMT mice. In contrast, in the hippocampus of the TMT+RTE mice, these mRNA expressions were significantly diminished (*c-fos*: 3.5 ± 1.6, *TNF-α*: 5.2 ± 2.5, *GFAP*: 1.6 ± 0.1 in the TMT+RTE100 group; Fig. 4A–C). These findings suggest that RTE may effectively reduce synaptic and neuroinflammatory mRNA expression levels.
3.4 Protective Effects of RTE against TMT-Induced Neuronal Inflammation

Representative photomicrographs presented in Fig. 5A show GFAP-positive astrocytes and Iba-1-positive microglia in the DG of the hippocampus in the control, TMT, and TMT+RTE mice. In the hippocampus, cells positive for both GFAP and Iba-1 exhibited a satellite-like morphology characteristic of mature astrocytes and microglia. The immunoreactivities of GFAP and Iba-1 were noticeably more pronounced in TMT-treated mice (GFAP: 4.46 ± 0.27, Iba-1: 5.21 ± 1.50) than those in the controls (GFAP: 1.00 ± 0.16, Iba-1: 1.00 ± 0.06; Fig. 5B,C). Furthermore, compared to the control cells, the GFAP- and Iba-1-positive cells exhibited thicker extended processes and hypertrophied cell soma. The TMT+RTE groups exhibited comparatively less pronounced immunoreactivities (GFAP: 1.42 ± 0.19, Iba-1: 1.35 ± 0.23 in the TMT+RTE100 group) and smaller cell diameters, suggesting that RTE may mitigate TMT-induced neuroinflammation.

3.5 Active Compounds in R. tanguticum

Within R. tanguticum, a total of 6 compounds were identified through UPLC analysis, while 92 were cataloged in the TCMSp database, and 31 in the HIT database. Compounds were considered for absorption, distribution, metabolism and excretion (ADME) profile analysis based on an OB value ≥30% and DL value ≥0.18, consistent with TCMSp standards [53]. After the ADME analysis, 19 active compounds was selected (Table 2) and arranged by their molecule ID as follows: eupatin, mutatochrome, physciondiglucoside, procyanidin B-5, 3′-O-gallate, rhein, sennoside E_qt, torachrysone-8-O-beta-D-(6′-oxayl)-glucoside, toralactone, emodin-1-O-beta-D-glucopyranoside, sennoside D_qt, daucosterol_qt, palmidin A, beta-sitosterol, aloe-emodin, gallic acid-3-O-(6′-O-galloyl)-glucoside, (-)-catechin, baicalin, baicalein, and cianidanol.

3.6 Overlapping Targets between R. tanguticum and Epilepsy from PPI Network

The integration of data from the TCMSp, HIT, and Swiss target databases led to the prediction of 455 targets associated with the 19 active compounds in R. tanguticum. From epilepsy-related databases, 432 specific targets were extracted. Cross-referencing these datasets revealed 35 common targets between R. tanguticum and epilepsy, indicating their potential as targets for R. tanguticum’s antiepileptic effects (Fig. 6A, Table 3). These targets were ranked by their predicted significance as follows: IL-6, AKT1, TNF, MTOR, IL-1β, FOS, PTGS2, ABCB1, RELA, SIRT1, NTRK2, CHRNA7, NR1I2, TGBF1, MAPT, CHRNA2, CHRM1, PTGS1, GABRA1, CHRM2, CYP2C19, OPRM1, GABRA2, OPRI1, CHRM3, ERN1, ILK, ABC2, GABRA5, ADRA2A, TNK2, RORA, COX3, AFG3L2, and ABCCS. The PPI network constructed using these 35 overlapping targets in the STRING database (Fig. 6B) was further analyzed in Cytoscape 3.9.0. This analysis produced a network comprising 32 nodes and 121 edges after removing 3 uncon-
Fig. 5. Histopathological changes in GFAP and Iba-1 after RTE administration on TMT-induced glial activation (A–C). GFAP and Iba-1 immunohistochemistry results expressed as mean ± standard error. **p < 0.01, ***p < 0.001 versus the controls. #p < 0.05, ##p < 0.01, ###p < 0.001 versus the TMT group. RTE, Rheum tanguticum root extract; TMT, trimethyltin; CON, control; GFAP, glial fibrillary acidic protein; Iba-1, ionized calcium-binding adaptor molecule-1.

nected nodes. From this network, the following top 10 node degrees were identified as key targets (Table 3, Fig. 6C): IL-6, AKT1 (degree = 16), TNF (degree = 15), MTOR, IL1B (degree = 14), FOS (degree = 13), PTGS2 (degree = 12), ABCB1, RELA, and SIRT1 (degree = 11).

3.7 GO and KEGG Pathway Enrichment Analyses

The 35 shared targets were subjected to KEGG pathway and GO term enrichment analysis using the DAVID database. A total of 34 pathways with significant enrichment having an adjusted p-value < 0.01 were identified. Among these, 15 prominent signaling pathways were selected for illustration (Fig. 7A). Notably, several pathways associated with neurodegenerative diseases and their mechanisms were underscored, including Alzheimer’s disease (hsa05010, p = 1.65 × 10^{-6}), pathways involved in neurodegeneration (hsa05022, p = 4.35 × 10^{-5}), neuroactive ligand-receptor interaction (hsa04080, p = 4.35 × 10^{-5}), and the TNF signaling pathway (hsa04668, p = 9.94 × 10^{-5}). Furthermore, 109 GO terms met the significance threshold with an adjusted p-value < 0.05, which encompassed 73 biological process terms, 19 cellular component terms, and 17 molecular function terms. The top 15 terms from these categories were visualized (Fig. 7B). In the “herb-compound-target-pathway” context, the principal active compounds connected to the 35 targets were betasitosterol (outdegree = 21), baicalein (outdegree = 10), eupalin (outdegree = 6), and aloe-emodin (outdegree = 6).
Table 2. List of all active compounds in *Rheum tanguticum* found in different databases.

<table>
<thead>
<tr>
<th>No.</th>
<th>Molecular ID</th>
<th>Molecule Name</th>
<th>OB (%)</th>
<th>DL</th>
<th>PubChemID</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>MOL002235</td>
<td>Eupatin</td>
<td>50.8</td>
<td>0.41</td>
<td>5317287</td>
</tr>
<tr>
<td>2</td>
<td>MOL002251</td>
<td>Mutatochrome</td>
<td>48.64</td>
<td>0.61</td>
<td>5281246</td>
</tr>
<tr>
<td>3</td>
<td>MOL002259</td>
<td>Physcionidiglucoside</td>
<td>41.65</td>
<td>0.63</td>
<td>442762</td>
</tr>
<tr>
<td>4</td>
<td>MOL002260</td>
<td>Procyanidin B-5,3'-O-gallate</td>
<td>31.99</td>
<td>0.32</td>
<td>162845209</td>
</tr>
<tr>
<td>5</td>
<td>MOL002268</td>
<td>Rhein</td>
<td>47.07</td>
<td>0.28</td>
<td>10168</td>
</tr>
<tr>
<td>6</td>
<td>MOL002276</td>
<td>Sennoside E_qt</td>
<td>50.69</td>
<td>0.61</td>
<td>162899601</td>
</tr>
<tr>
<td>7</td>
<td>MOL002280</td>
<td>Torachrysone-8-O-beta-D-(6'-oxayl)-glucoside</td>
<td>43.02</td>
<td>0.74</td>
<td>163001298</td>
</tr>
<tr>
<td>8</td>
<td>MOL002281</td>
<td>Toralactone</td>
<td>46.46</td>
<td>0.24</td>
<td>5321980</td>
</tr>
<tr>
<td>9</td>
<td>MOL002288</td>
<td>Emodin-1-O-beta-D-glucopyranoside</td>
<td>44.81</td>
<td>0.8</td>
<td>11968447</td>
</tr>
<tr>
<td>10</td>
<td>MOL002293</td>
<td>Sennoside D_qt</td>
<td>61.06</td>
<td>0.61</td>
<td>135397905</td>
</tr>
<tr>
<td>11</td>
<td>MOL002297</td>
<td>Daucosterol_qt</td>
<td>35.89</td>
<td>0.7</td>
<td>5742590</td>
</tr>
<tr>
<td>12</td>
<td>MOL002303</td>
<td>Palmidin A</td>
<td>32.45</td>
<td>0.65</td>
<td>5320384</td>
</tr>
<tr>
<td>13</td>
<td>MOL000358</td>
<td>Beta-sitosterol</td>
<td>36.91</td>
<td>0.75</td>
<td>222284</td>
</tr>
<tr>
<td>14</td>
<td>MOL000471</td>
<td>Aloe-emodin</td>
<td>83.38</td>
<td>0.24</td>
<td>10207</td>
</tr>
<tr>
<td>15</td>
<td>MOL000554</td>
<td>Gallic acid-3-O-(6’-O-galloyl)-glucoside</td>
<td>30.25</td>
<td>0.67</td>
<td>162995045</td>
</tr>
<tr>
<td>16</td>
<td>MOL000096</td>
<td>(-)-Catechin</td>
<td>49.68</td>
<td>0.24</td>
<td>73160</td>
</tr>
<tr>
<td>17</td>
<td>C1125</td>
<td>Baicalin</td>
<td>40.12</td>
<td>0.75</td>
<td>64982</td>
</tr>
<tr>
<td>18</td>
<td>C1114</td>
<td>Baicalin</td>
<td>33.52</td>
<td>0.21</td>
<td>5281605</td>
</tr>
<tr>
<td>19</td>
<td>C1241</td>
<td>Cianidanol</td>
<td>54.83</td>
<td>0.24</td>
<td>9064</td>
</tr>
</tbody>
</table>

OB, oral bioavailability; DL, drug-likeness.

Table 3. Top 10 protein-protein interaction (PPI) network target proteins of *Rheum tanguticum* in epilepsy.

<table>
<thead>
<tr>
<th>No.</th>
<th>Symbol</th>
<th>Uniprot ID</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>IL-6</td>
<td>P05231</td>
<td>Interleukin-6</td>
</tr>
<tr>
<td>2</td>
<td>AKT1</td>
<td>P31749</td>
<td>RAC-alpha serine/threonine-protein kinase</td>
</tr>
<tr>
<td>3</td>
<td>TNF</td>
<td>P01375</td>
<td>Tumor necrosis factor</td>
</tr>
<tr>
<td>4</td>
<td>MTOR</td>
<td>P42345</td>
<td>Mammalian target of rapamycin</td>
</tr>
<tr>
<td>5</td>
<td>IL-1β</td>
<td>P01584</td>
<td>Interleukin-1 beta</td>
</tr>
<tr>
<td>6</td>
<td>FOS</td>
<td>P01100</td>
<td>Protein c-fos</td>
</tr>
<tr>
<td>7</td>
<td>PTGS2</td>
<td>P35354</td>
<td>Prostaglandin G/H synthase 2</td>
</tr>
<tr>
<td>8</td>
<td>ABCB1</td>
<td>P08183</td>
<td>ATP-dependent translocase ABCB1</td>
</tr>
<tr>
<td>9</td>
<td>RELA</td>
<td>Q04206</td>
<td>Transcription factor p65</td>
</tr>
<tr>
<td>10</td>
<td>SIRT1</td>
<td>Q96EB6</td>
<td>NAD-dependent protein deacetylase sirtuin-1</td>
</tr>
</tbody>
</table>

The central proteins were noted for their involvement in a greater number of signaling pathways than were the other proteins. For instance, TNF was implicated in multiple pathways, including those related to neurodegeneration and the TNF signaling pathway (Fig. 8).

### 4. Discussion

The primary objective of pharmacotherapy in the management of epilepsy is to achieve complete remission of epileptic seizures. Medications targeting the reduction of neuronal excitation or the augmentation of inhibitory processes through various mechanisms, such as gamma-aminobutyric acid (GABA)-receptor enhancement, inhibition of glutamate excitation, or the modulation of voltage-gated sodium and calcium channels, are widely utilized [54]. Nevertheless, studies indicate that over 30% persons with epilepsy exhibit resistance to antiepileptic drugs [55]. Furthermore, the prolonged use of these medications is often associated with somatic, neurological, psychiatric, and neonatal adverse effects, posing significant challenges to epilepsy pharmacotherapy [56]. This situation underscores the urgent need for research regarding natural substances that possess antiepileptic properties through novel mechanisms.

Our study demonstrates that RTE mitigates the severity of TMT-induced epileptic seizures and associated weight loss in a dose-dependent manner (Fig. 3B,C). *R. tanguticum*, which is one of the source plants for Daehwang, a recognized medicinal in China, Korea, and Japan, was utilized in this investigation. Hepatotoxicity of Daehwang has been previously reported [57,58], so clinical use requires toxicity control, such as compliance with appropriate dosage and use of hot water extraction method. The recommended dosages for Daehwang are documented in the pharmacopeias of these nations, and it is available commercially as a raw component for herbal preparations.
neuroprotective effects of *R. tanguticum* as a part of the formulation, *Geijigadaehwang-tang* has been studied previously [32], and our findings confirm its antiepileptic and neuroprotective potential. However, variations in the therapeutic effects may arise depending on the geographical location of the source and processing of the plants used as *Daehwang*, which warrants further research. Moreover, the chronic toxicity assessments of rhubarb extract have indicated a NOAEL of 94 mg/kg/day, reflecting a range of biological safety in several contexts [35]. Our findings showed no significant change in body weight for dosages from 10 to 100 mg/kg/day, with RTE notably inhibiting the weight loss associated with TMT-induced neurotoxicity (Fig. 3B).

Therefore, we conducted a component analysis to verify the quality standards and identify the constituents of *R. tanguticum*. Sennoside A, sennoside B, chrysophanol, emodin, physcion, (+)-catechin, and quercetin-3-O-glucuronide were identified as components in RTE by UPLC (Fig. 2). These findings conform to the results of the component analyses of rhubarb and *Daehwang* performed in previous studies [57,58]. Various research efforts have underscored the neuroprotective properties of these constituents. For example, sennoside derivatives have shown potent antioxidative effects against oxidative stress induced by hydrogen peroxide, light, and radiation, mitigating the production of reactive oxygen species production and neutralizing free radicals [59,60]. Chrysophanol has been noted for its efficacy in reducing inflammation in focal ischemic brain injuries and decreasing proinflammatory cytokines, including TNF-α and

---

**Fig. 6.** Target analysis of *Rheum tanguticum* for epilepsy treatment from various databases. (A) Intersection of 35 targets between *R. tanguticum* and epilepsy. (B) Protein-protein interaction network intensity of the 35 overlapping targets. (C) Topology analysis of the protein-protein interaction network. Targets are represented by circular nodes, and larger nodes denote higher significance.
Interleukin-1 beta (IL-1β) [61]. Emodin has been recognized for its potential to reduce neurotoxicity in numerous neurological disorders, such as anxiety, depression, cerebral ischemia, Alzheimer’s disease, Parkinson’s disease, and schizophrenia [62]. Physcion has been validated to confer protection against neuronal damage from cerebral ischemia-reperfusion by inhibiting the Toll-like receptor 4/nuclear factor kappa-light-chain-enhancer of activated B cells (TLR4/NF-κB) pathway [63]. Catechin is widely recognized for its neuroprotective effects and has been extensively investigated for its antioxidant and iron-chelating properties, which protect against neurodegenerative diseases like Parkinson’s disease and Alzheimer’s disease [64]. Finally, quercetin-3-O-glucuronide has been found to protect neurons from Parkinson’s disease in animal models, such as the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and rat 6-hydroxydopamine (6-OHDA) models, by suppressing reactive oxygen species and hindering apoptosis [65,66].

Additional active compounds, including (-)-catechin, sennoside D, sennoside E, and aloe-emodin, which are isomers of those verified by the UPLC technique were iden-
Fig. 8. Network herb-compound-target-pathway of *Rheum tanguticum* in treating epilepsy. The herb is represented by the green node, compounds by orange nodes, targets by blue nodes, and pathways by purple nodes.

tified by the *in silico* PPI analysis (Table 2). The compound, rhein is primarily known for its neuroprotective effects, which are attributed to its antioxidant and anti-inflammatory properties [67,68]. Similarly, baicalein has been shown to be effective in a range of epilepsy models, including temporal lobe and posttraumatic epilepsy ones [69,70]. Owing to the lack of available standards, only a subset of the RTE components were identified by UPLC. However, compounds similar to rhein and baicalein, though not directly identified, may be present in RTE. *In silico* methods help estimate the other RTE constituents that may contribute to seizure inhibition and neuroprotection. Therefore, despite discrepancies between computer simulation and component analysis, both strands of evidence corroborate the therapeutic potential of *R. tanguticum* root in treating epilepsy.

TMT is known to be associated with neurodegeneration in the central nervous system, especially in the hippocampus. The pathogenic mechanisms of TMT involve several processes, including oxidative stress, neuroinflammation, neuronal death, and regeneration [25]. While the precise mechanisms remain unclear, glutamate-mediated excitotoxicity and calcium dysregulation by TMT play important roles in the pathophysiology of epilepsy [71]. In our study, mice exposed to TMT exhibited aggressive behavior and seizures, which resemble symptoms of degenerative brain disorders [28]. When RTE was administered to these mice, an amelioration of these clinical symptoms was observed on the first and second days after treatment (Fig. 3B,C).

DCX is found in proliferating neural progenitors and neuronal precursors during adult neurogenesis and serves as a reliable marker for neurogenesis in adult brains [72]. Adult mouse hippocampi typically exhibit high DCX levels. However, a previous study showed that DCX expression markedly reduced after a 2–4-day exposure to TMT, with notable recovery observed on the 10th day after exposure [73]. We found that adult neurogenesis significantly reduced 2 days after TMT treatment, although RTE administration prevented this neuronal degeneration (Fig. 3D,E). Additionally, neuronal death has been identified as a critical factor in epileptogenesis [52]. Our study suggests that RTE treatment mitigates TMT-induced neuronal degeneration and epilepsy-like behavior.

C-fos is recognized as a marker of neural activity and is associated with cellular development, differentiation, transformation, and death [74,75]. After a seizure, c-fos activation is noticeable in the brain [76]. Previous studies have shown increased c-fos expression following TMT administration, which is correlated with the intensity of seizure behaviors that was highest 2 days after administration [38]. In our study, RTE lowered the mRNA expression of c-fos, thus mitigating seizure behaviors (Fig. 4A). Additionally, within the PPI network, both TNF (degree = 15) and Protein c-fos (FOS, degree = 13) were identified as central proteins in the context of epilepsy treatment (Fig. 6).

TNF-α is a major inflammatory regulator capable of inducing further cytokine production and potential neuronal death [77]. It may precipitate neuroinflammation and promote DG cell death in the TMT model [78,79]. TMT exposure causes the activation of astrocytes and significant release of inflammatory cytokines, such as TNF-α, which are detrimental to the brain [80]. We found that RTE treatment reduced the production of both TNF-α and GFAP (Fig. 4B,C), thereby offering protection against TMT-induced neuronal inflammation in the hippocampus. Consequently, our *in vivo* and *in silico* results suggest that proteins such as FOS and TNF play significant roles in neuroprotective activity.

The morphological analysis of the PPI network extended beyond c-fos, TNF-α, and GFAP, and critical RT proteins implicated in seizures, including Interleukin (IL)-6, RAC-alpha serine/threonine-protein kinase (AKT1), Mammalian target of rapamycin (mTOR), and IL-1β, were identified (Table 3). Both experimental and clinical research have underscored the pivotal role of cytokines, including IL-6 and IL-1β, in the underlying pathophysiological mechanisms of epilepsy [81,82]. Moreover, mTOR is
recognized as a fundamental component of nervous system functionality, and mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) function together to regulate neural network activity, dendritic architecture, synaptic function, and generation of new neurons, all of which are essential for cortical brain development [83]. Collectively, our integrated approach, combining experimental study and network pharmacology, highlights the potential of *R. tanguticum* to confer neuroprotection in the management of epilepsy by modulating proteins and pathways associated with neurodegeneration.

The implications of this study for clinical practice are indirect and preliminary, offering foundational insights for translational research in treating neurodegenerative conditions. While we did not investigate the effect of varied concentrations of *Daehwang* extract for extended treatment durations, our findings lay the groundwork for subsequent experimental investigations involving these compounds.

### 5. Conclusions

In summary, this study identified the components of RTE and demonstrated its *in vivo* anti-toxic activity against TMT damage. Concurrently, RTE was observed to attenuate the clinical symptoms of seizures, reduce hippocampal neurogenesis, and increase glial activation. Complementary to these findings, network pharmacology approaches revealed that 19 active compounds in RTE, interacting with 35 distinct targets, are integral to its antiepileptic efficacy. These compounds appear to exert their beneficial effects by modulating pathways associated with neurodegeneration and TNF signaling. Collectively, our findings suggest that RTE may possess therapeutic promise for conditions such as epilepsy and neurodegenerative diseases by counteracting inflammatory and oxidative pathways.

### Availability of Data and Materials

Data generated or analyzed during this study are included in this published article.

### Author Contributions

JC, SL, JSK, and SIL conceived and designed the experiment. SK, MNT, SMR, DHK, YEL, SWC, and SJ performed the experiments. JC, SMR, CM, SL, and JSK analyzed and interpreted the data. JC, SMR, JSK, CM, and SIL contributed reagents, materials, analysis tools or data. JC, SK, JSK, MNT, and SIL wrote the paper. SWC, JSK, and SIL wrote the review and editing. SWC acquired grant funding. All authors contributed to editorial changes in the manuscript. All authors read and approved the final manuscript. All authors have participated sufficiently in the work and agreed to be accountable for all aspects of the work.

### Ethics Approval and Consent to Participate

All experimental procedures were conducted in accordance with the protocols approved by the Institutional Animal Care and Use Committee at Dongshin University (Approval No.: DSU2023-04-03).

### Acknowledgment

Not applicable.

### Funding

This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2021R1A2C1009604).

### Conflict of Interest

The authors declare no conflict of interest. Changjong Moon is serving as one of the Editorial Board members/Guest editors of this journal. We declare that Changjong Moon had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Jesús Pastor and Gernot Riedel.

### References


Koczyk D, Oderfeld-Nowak B. Long-term microglial and astroglial activation in the hippocampus of trimethyltin-

